Erlotinib (Multichem)

Ülke: Yeni Zelanda

Dil: İngilizce

Kaynak: Medsafe (Medicines Safety Authority)

Aktif bileşen:

Erlotinib hydrochloride 163.9mg equivalent to erlotinib 150mg

Mevcut itibaren:

Multichem NZ Limited

Doz:

150 mg

Farmasötik formu:

Film coated tablet

Kompozisyon:

Active: Erlotinib hydrochloride 163.9mg equivalent to erlotinib 150mg Excipient: Opadry White 20B58900 Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium laurilsulfate Sodium starch glycolate

Reçete türü:

Prescription

Terapötik endikasyonlar:

· Erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations. · Erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who have previously received chemotherapy.

Ürün özeti:

Package - Contents - Shelf Life: Blister pack, PVC/Al foil strips in cardboard carton - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Yetkilendirme tarihi:

2020-04-15